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PMD5
ReDucing insulin syRinge Reuse can HelP loweR cost of insulin 
waste in BRazil
DiMario S, Chandran A
Becton Dickinson, Franklin Lakes, NJ, USA
Objectives: Brazil ministry of health guidance for diabetes management allows 
for an insulin needle to be reused 8 times. Reuse has been associated with lipo-
hypertrophy. Additionally, diabetes patients with lipohypertrophy require higher 
doses of insulin. This analysis demonstrates potential cost savings from syringe 
reuse reduction in Brazil. MethOds: A budget impact model was created to dem-
onstrate the relationship between lower syringe reuse and lipohypertrophy rates. 
It was assumed 90% of patients use syringes in Brazil. An international survey 
suggests the lipohypertrophy rate is 48%. Another study showed increasing reuse 
correlates to a higher ratio of lipohypertrophy presence. With estimates including 
additional insulin requirements for lipohypertrophy, cost of insulin, and annual 
cost and volume of syringes, the difference between insulin wasted from lipohyper-
trophy and the cost associated with reducing reuse rate was calculated. Results: 
The estimated insulin injecting population with lipohypertrophy using syringes in 
Brazil is 691,200. If these patients require 15 units more insulin/day and the cost/
unit is $0.03, then the cost of excess insulin is $113.5 million/yr. The difference in 
rate of lipohypertrophy between reusing 8x (rate of 5.5) and reusing 4x (rate of 2.2) 
is a factor of 2.5. Based on estimated cost, volume, and currently allowed reuse 
rate, Brazil spends approximately $22.8 million on insulin syringes. If a reuse rate 
of 4x was implemented ($45.6 million), Brazil could anticipate a lipohypertrophy 
reduction of 28.8%, and a $68.1 million decrease in excess insulin. The savings on 
excess insulin and the incremental investment in syringes ($22.8 million) Resultsin 
a total savings of $45.3 million/yr. cOnclusiOns: The current acceptable reuse rate 
in Brazil, 8x, may be driving increased diabetes management costs. Best practice 
advocates single use. However, if Brazil cuts their reuse guidance in half, they can 
save $45.3 million/yr from reduced insulin waste.
PMD6
BuDget iMPact analysis of DRug coateD Balloon vs. PeRcutaneous 
tRansluMinal Balloon angioPlasty in tHe tReatMent of PeRiPHeRal 
aRteRial Disease in loweR liMBs in BRazil
Pepe C1, Fahham L2, Follador W3, Valencia J4, Orozco JJ5
1Grupo Resulta, São Paulo, Brazil, 2Sense Company, São Paulo, Brazil, 3Medtronic, São Paulo, 
Brazil, 4Medtronic, Miami, FL, USA, 5Medtronic, Medellin, Colombia
Objectives: Budget Impact analysis (BIA) of Drug Coated Balloon (DCB) vs. 
Percutaneous Transluminal Balloon Angioplasty (PTA) in the treatment of 
Peripheral Arterial Disease in lower limbs in Brazil. MethOds: A BIA was per-
formed to assess the incremental budget impact of the incorporation, to the 
Brazilian public healthcare system, of a method of PTA using a drug coated bal-
loon compared to the currently available technology, using an standard balloon, 
on the treatment of the peripheral arterial disease, in a 5 years’ time horizon. The 
total amount of PTA procedures on the system was extracted from DATASUS, a 
nation-wide, anonymous, public healthcare claims database, between 2008 and 
2013. Based on this data, the eligible population was projected linearly for the years 
between 2014 and 2019. Total costs (angioplasty plus surgical revascularization in 
case of a TLR) per procedure were based on an analytic decision model (R$ 4,415.70 
(DCB); R$ 3,720.03 (PTA)). It was assumed that, after the incorporation, all patients 
eligible to a PTA will undergo the procedure using a DCB instead of the standard 
balloon. Results: The DCB incorporation showed an impact of R$ 1.9 million on 
the first year (2015) and reached a total amount of R$ 11.8 million in 5 years. The 
projected impact for the year of 2015 (R$ 1.9 million) represents less than 0.01% of 
the budget destined to hospital and ambulatory assistance. cOnclusiOns: The 
incorporation of DCB for the treatment of Peripheral Arterial Disease in Lower 
Limbs in the Brazilian public healthcare system has low budget impact and it 
would represent less than 0.01% of the budget destined to hospital and ambula-
tory assistance.
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econoMic Benefits associateD witH nt-PRoBnP test in BRazil anD 
Mexico
Franco Figueira S1, Cachoeira CV1, Souza FH1, Kano BY1, Petry Hasegawa AC2,  
Bertozzi da Conceicao Duarte G3
1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Brazil, São Paulo, Brazil,  
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Objectives: The objective of this study is to investigate the economic impact per 
patient using NT-proBNP test to guide the diagnostic assessment and management 
of dyspneic patients in the Emergency Department in Brazil and Mexico. MethOds: 
A cost tool was developed based on a decision tree from Siebert study. It was evalu-
ated the standard clinical assessment (strategy 1) with assessment guided by 
NT-proBNP (strategy 2), from a payer’s perspective. The direct medical costs were 
based on the DATASUS (Departamento de Informática do Sistema Único de Saúde – 
Brazil) and IMSS (Instituto Mexicano del Seguro Social – Mexico) databases converted 
to 2015 US dollars (USD). The time horizon was 60 days. Additionally, the sensitivity 
analysis was performed with a variation of 10%. Results: Based on Siebert study, 
the optimal use of NT-pro-BNP strategy reduces the use of echocardiography from 
25% to 10.5% and the average of hospitalization length from 4.41 days to 3.88 days. 
Therefore, according to our cost tool for Brazil, in the base case scenario, the sav-
ings per patient is $218.15, after applying the sensitivity analysis in the best case 
scenario the savings achieved is $385.23, and in the worst case is $51.07. A similar 
result could be achieved in Mexico, in the base case scenario the savings per patient 
is $218.96, while with the sensitivity analysis the savings reached $388.55 for the 
best case scenario, and $74.50 for the worst case. cOnclusiOns: The optimal use of 
NT-proBNP test could improve the management of patients with acute Heart Failure 
according to our analysis. Moreover, it demonstrated incremental value in diagnosis 
which may result in improved therapeutic decisions and savings for both countries.
1PL Shupyk National medical academy of postgraduate education, Kyiv, Ukraine, 2The National 
Technical University of Ukraine “Kyiv Polytechnic Institute”, Kyiv, Ukraine
Objectives: Cervical cancer (CC) takes the 3rd place among women cancers glob-
ally, accounting for more than quarter of a million deaths annually. In Ukraine it 
takes the 2nd place of cancers among women aged 15 to 44, accounting for more 
than 2000 deaths each year. Gradual increase of CC incidence rates during the previ-
ous decade is concurrently followed by the decrease of a median age of diagnosis. 
Incidence rates for CC in Ukraine are estimated to be at least two times higher 
than in countries with well-organized cervical screening programs. Thus the aim 
of this study is to evaluate the most efficient cervical screening strategies using 
“cost-utility” method. MethOds: “Cost-utility”-based analysis and evaluation are 
based on the Resultsof own clinical and laboratory studies of 1257 cervical samples 
(HPV DNA tests and cytological diagnostics) from women aged 19 – 65 (mean age 
30.68 (±7.72)), living in different regions of Ukraine. Statistical and mathematical 
Methodsare used for modeling the utility function of a number of diagnostic strat-
egies. Analytical representation and evaluation of the data was performed using 
MATLAB Simulink r2014a software package. Results: Initial hypothesis of the 
utility function form for HPV DNA and cytological tests was put forward. It was 
assumed that the first test has a maximum utility at a defined age limit due to the 
age-dependent increase of the probability of cytological test being positive. This 
Resultsin reduction of the predictive utility of HPV DNA test. The utility function of 
cytological test must resemble cumulative sigmoid function. Stated hypothesis was 
verified on the data on HPV DNA presence in normal cytology and cervical intraepi-
thelial lesions using Methodsof mathematical modeling. cOnclusiOns: The study 
confirmed given hypothesis. The obtained Resultscan be used in “cost-utility”-based 
method of pharmacoeconomic analysis of different cervical screening strategies
PMD3
effectiveness of tHe antiBiotic-iMPRegnateD catHeteRs in 
ventRiculaR DRainage in HyDRocePHalus Patients – a systeMatic 
Review
Oliveira FM1, Oliveira D1, Andrade PC2, Luque A2, Junqueira Junior SM1, Cabra HA3
1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson&Johnson Medical Brazil, Sao Paulo, 
Brazil, 3Johnson & Johnson Medical, México, D.F., Mexico
Objectives: The ventricular drainage of the cerebrospinal fluid (CSF) is an essen-
tial procedure in the care of patients with hydrocephalus and intracranial hyper-
tension. However, the literature shows evidences of an infection rate (IR) of 5% to 
10%. Infections can cause neurological sequelae and death. To reduce the risk of 
contamination antibiotic-impregnated catheters (AIC) are indicated. The aim of 
this study is to systematic review (SR), the efficacy of these catheters. MethOds: 
The electronic databases, MEDLINE via Pubmed, The Cochrane Central Register of 
Controlled Trials, The Cochrane Library, LILACS, CRD and EMBASE were reviewed 
until June, 2013. No language and time limits were applied. Meta-analysis, SR 
and RCTs in patients using AIC in the hydrocephalus treatment with internal 
or external shunt comparing to standard catheter (SC) were included in this 
study. Results: 232 records were identified. 45 studies were revaluated. 4 met 
the inclusion criteria – 3 SR and 1 RCT. The first SR evaluated 14 studies. Among the 
9,049 cases evaluated, SC and AIC presented an IR of 7.0% and, 3.5% respectively. 
The second SR evaluated 2,664 cases and observed a global and pediatric IR of 7.2% 
(SC) and 3.3% (AIC) and 11.2% (SC) and 5.0% (AIC). The third SR showed though a 
meta-analysis, similar Resultsfor the adult and pediatric population and included 
the neonate where they observed a significant difference for the AIC in internal 
shunts: RR:0.37; IC:0.16-0.86; p= 0.02. The RCT evaluated the IR for SC and AIC and 
found a not statistically significant lower IR in the AIC, probably because of the 
low global IR. cOnclusiOns: The studies suggest AIC reduces infections related 
to drainage especially in the pediatric population.
MeDical Device/Diagnostics – cost studies
PMD4
BuDget iMPact MoDel foR ceRvical canceR scReening using HPv tests 
in cHile
Franco Figueira S1, Cachoeira CV1, Souza FH1, Kano BY1, Silva M2, Poulios N3
1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Chile, Santiago, Chile, 3 
Roche Molecular Systems, Inc., Pleasanton, CA, USA
Objectives: The aim of this study is to estimate, in Chile, the clinical and budget 
impact of cervical cancer primary screening with a HPV-16/18 genotyping test which 
simultaneously detects 12 other high-risk HPV types. MethOds: A decision tree 
framework was used to model the screening and diagnosis of cervical cancer to com-
pare three strategies: (1) Cytology alone – Screening Interval (SI): 3 years; (2) Pooled 
HPV with reflex cytology – SI: 5 years; (3) HPV with 16/18 genotyping and reflex 
cytology (cobas® 4800) – SI: 5 years, from a payer’s perspective. The impact model 
was run by having the women cohort progress through the model with 2 screening 
cycles. In addition, the screening and cancer treatment costs were calculated from 
FONASA public data (Fondo Nacional de Salud) reported in 2014 converted to US dol-
lars (USD). Results: The Budget Impact Model indicates that, when comparing the 
Strategy 2 and 3 to Strategy 1 there is an increase of ≥ CIN2 (Cervical Intraepithelial 
Neoplasia) cases detected, treated and a reduction at the number of patients pro-
gressing to cervical cancer. When comparing the strategy 2 to strategy 1, the model 
estimated savings of 1.9% at the annual costs, including screening, diagnosis and 
treatment. There is also a decrease of 25% and 33% at the incidence of Cervical 
Cancer and Mortality Rate, respectively. Better clinical Resultscould be achieved 
when the strategy 3 is implemented. An additional investment of only 0.37% at the 
annual budget would be necessary to decrease the incidence of Cervical Cancer by 
43% and the mortality rate by 54% in Chile. cOnclusiOns: This analysis suggests 
that the use of the HPV genotyping test (strategy 3) is a potential effective manage-
ment strategy, given that the clinical impacts are highly positives and budgetary 
impact is basically neutral, comparing to the current screening program in Chile.
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uncertainties, considering main clinical parameters, technologies´ accuracy, spe-
cific cost items and discount rate. Results: With conventional strategy 1,875 
cases of recurrence were identified after 10 years of follow-up. Use of 18FDG-PET/
CT allowed detection of only 13 additional cases (1,888 cases on total), but at 
significant cost. As a result, each additional case of recurrence detected by 18FDG-
PET/CT would cost R$ 477,633.05 in discounted values (US$ 296,666.50 in 2013 PPP 
rate). In univariate sensitivity analysis, parameters that produced greater reduc-
tion in ICER were 18FDG-PET/CT costs, accuracy of competing technologies and 
discount rate. Probabilistic sensitivity analysis showed considerable uncertainty 
about the costs and potential incremental benefits of 18FDG-PET/CT addition to 
conventional management. cOnclusiOns: Although 18FDG-PET/CT inclusion to 
DTC metastatic recurrences detection promotes the identification of additional 
cases, the aggregate costs are very significant and its introduction is not cost-
effective in the SUS perspective.
PMD12
evaluación econóMica coMPleta Del escáneR ceRvical avanzaDo 
coMo agente Diagnóstico en Pacientes Mexicanas con Riesgo 
asociaDo a cánceR De céRvix PoR vPH en México
Sanchez K1, Soto H1, Escobar Juárez Y2
1Universidad Autonoma Metropolitana, México D.F., Mexico, 2HS Estudios Farmacoeconómicos, 
Mexico City, Mexico
ObjectivOs: Realizar un análisis de costo-efectividad del uso del escáner cer-
vical (como agente diagnóstico en pacientes mexicanas con riesgo asociado a 
cáncer de Cérvix por VPH, desde el punto de vista del sector público de salud en 
México. MetOdOlOgíAs: La población objetivo del estudio fueron pacientes que 
tuvieron resultados positivos en prueba de PAP y necesitan una segunda prueba para 
identificar verdaderos positivos. Para demostrar la eficiencia del escáner cervical 
en esta población se realizó un análisis de costo-efectividad mediante el diseño 
de un árbol de decisiones para comparar el escáner cervical vs colposcopía con un 
horizonte temporal de 5 años. Se considera como medida de eficacia los verdaderos 
positivos identificados por cada intervención, los costos calculados corresponde a 
los verdaderos positivos no identificados a tiempo y el costo de ambas pruebas. Se 
ejecutó un análisis de sensibilidad univariado modificando: el costo, la efectividad, 
el horizonte temporal, pacientes atendidos al año, se realizó también un análisis 
de sensibilidad probabilístico. ResultAdOs: Los resultados para escáner cervical 
mostraron un costo de $81,905,308.55 pesos con 13,380 verdaderos positivos identi-
ficados, para colposcopía el costo fue de $210,942,475.77 pesos con 8,134 verdaderos 
positivos identificados en el horizonte temporal de 5 años considerando que se 
pueden tratar 9,300 pacientes al año. Los análisis de sensibilidad demostraron que 
el escáner cervical siempre se mantuvo dominante al variar los parámetros que 
podrían generan mayor incertidumbre. cOnclusiOnes: La opción de escáner cer-
vical es costo-efectiva para el sistema de salud pública en México siendo dominante 
frente a colposcopia, considerada el estándar de atención en mujeres que han dado 
positiva la prueba PAP, al identificar un mayor número de verdaderos positivos y 
de esa forma dar un tratamiento preventivo a pacientes con virus de VPH antes de 
desarrollar cáncer cervicouterino.
PMD13
evaluaci”n De costo-efectiviDaD De la iMPleMentaci”n De MonitoReo 
aMBulatoRio De PResi”n aRteRial veRsus PeRfil De PResi”n aRteRial 
PaRa el Diagn”stico De HiPeRtensi”n en el sisteMa PúBlico cHileno
Bittner M1, Espinoza MA2, Montero J1
1Pontificia Universidad Católica de Chile, Santiago, Chile, 2Catholic University of Chile, Santiago, 
Chile
ObjectivOs: En Chile el diagnóstico de hipertensión arterial se basa en el Perfil de 
Presión Arterial (PPA), el cual tiene una sensibilidad y especificidad de 74,7% y 74,8% 
respectivamente. Por otro lado, el Monitoreo de Presión Arterial (MAPA) es considerado 
el Gold Standard de diagnóstico. El objetivo del presente estudio es evaluar la costo-
efectividad de implementar MAPA versus PPA, para el diagnóstico de hipertensión 
arterial (HTA) desde la perspectiva del sistema público chileno. MetOdOlOgíAs: 
Análisis de costo-efectividad. Se utilizó un modelo mixto (Árbol de Decisiones y 
Markov) para estimar costos (pesos chilenos 2014) y beneficios esperados (QALYS) en 
hombres y mujeres. Las probabilidades de transición y utilidades fueron obtenidas de 
la literatura, ponderando por la prevalencia de otros factores de riesgo cardiovascular. 
Los costos se extrajeron del estudio de verificación 2009 del Ministerio de Salud. Se 
utilizó una tasa de descuento de 3% para costos y utilidades, y se modeló un tiempo 
horizonte de 60 años. Los resultados son presentados como beneficios netos incre-
mentales (BNI) y como razón incremental de costo efectividad (RICE). Esta última fue 
sensibilizada para múltiples parámetros. ResultAdOs: El costo esperado para MAPA 
fue menor al estimado para PPA, mientras que los QALYs esperados fueron mayores, 
resultando una RICE de $-234.045 para hombres y $-1.867.799 para mujeres. Los BNI 
para distintos valores del umbral muestran que MAPA sigue siendo costo efectiva 
incluso con valores de umbral superiores a 3 producto interno bruto per capita (PIBpc). 
El análisis de sensibilidad determinístico de una vía evaluó cambios de +/- 10% en 
cada variable. En ningún caso la RICE sobrepasó el umbral de referencia para Chile 
de 1 PIBpc. cOnclusiOnes: MAPA es una estrategia diagnóstica costo-efectiva para 
el diagnóstico de HTA en el Sistema de Salud Público chileno.
PMD14
costo efectiviDaD De MúltiPles alteRnativas Diagn”sticas en 
Pacientes con sosPecHa De cánceR De PulM”n en coloMBia
Guevara CA1, Parody E1, Aguirre AF2
1Icesi University, Cali, Colombia, 2Researcher Center for Social Protection and Health Economic, 
Cali, Colombia
ObjectivOs: Determinar la eficiencia de múltiples alternativas diagnósticas en 
pacientes con lesiones sugestivas en las imágenes para el diagnóstico de cáncer de pul-
món de célula no pequeña. MetOdOlOgíAs: Se realizó un estudio de costo efectividad 
basado en un árbol de decisión desde la perspectiva del pagador de mediastinoscopia, 
PMD8
coMPaRação De custos e efetiviDaDe entRe Ml- flow e BaciloscoPia 
PaRa auxílio Diagn”stico e tRataMento Da Hanseníase
Freitas M1, Godoy MR2, Barcellos N2, Kroeff L2, Balbinotto Neto G3, Itria A4
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Federal de Goiânia, Goiânia, Brazil
ObjetivOs: Mensurar os custos e efetividade do diagnóstico laboratorial da 
hanseníase através de dois exames: baciloscopia, que o exame adotado no sistema 
de saúde, e o ML-Flow, que é um teste rápido, sem registro sanitário, e utilizado no 
diagnóstico de 13.457 pacientes no Brasil, Índia, Chile, Nigéria, Nepal, Indonésia 
e Filipinas. MétOdOs: Entre junho de 2010 e outubro de 2011, realizou-se um 
ensaio clínico no Centro de Referência Estadual de Hanseníase do Ambulatório 
de Dermatologia Sanitária de Porto Alegre. Foram avaliados todos pacientes (n:35) 
atendidos com suspeita de hanseníase através de exame clínico, como preconi-
zado pela Organização Mundial de Saúde, e por dois testes laboratoriais: bacilosco-
pia e ML-Flow. Foram computados os custos de aquisição dos testes e insumos, e 
da mão de obra da equipe multidisciplinar envolvida. Foram ainda calculados os 
custos de tratamento para as duas formas de hanseníase: multibacilar e pauci-
bacilar. Ressalta-se que não há padrão-ouro na detecção da hanseníase e a con-
firmação laboratorial auxilia na definição do tratamento. ResultAdOs: A idade 
média dos pacientes foi de 51,7 anos; 62,9% residiam na região metropolitana; 
60% do sexo feminino; 88,6% classificados como multibacilares. A baciloscopia 
apresentou resultado positivo em 18 (51,43%) pacientes. O ML-Flow foi positivo 
em 22 (62,86%). Em pacientes multibacilares, o custo da estratégia bacilosco-
pia foi de R$209,26 e do ML-Flow foi de R$93,82. Em pacientes paucibacilares, o 
custo total foi de R$89,51 e R$31,97, respectivamente. Na análise de sensibilidade 
bivariada foram reduzidos os custos de mão de obra e duplicado o custo do teste 
rápido, mesmo assim a estratégia ML-Flow permaneceu apresentando menor 
custo total. cOnclusões: O ML-Flow é mais sensível e diagnosticou 4 (11,43%) 
casos a mais de casos de hanseníase do que a baciloscopia. Além disto, o novo 
teste diagnóstico apresentou menor custo total, independente da forma bacilar da 
doença. Estes resultados sugerem que a utilização do teste rápido para detecção 
de hanseníase proporciona economia de recursos.
PMD9
stanDaRDs of suRgical MateRials usage in anteRioR cRuciate 
ligaMent (acl) suRgeRy in BRazil unDeR tHe PeRsPective of tHe 
PRivate HealtH caRe systeM
Pegoretti B1, Paladini L2, Medina P1, Castro AP1, Alves AF1, Clark OA1
1Evidencias - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, Campinas, Brazil
Objectives: To describe the standards of the surgical approach, in terms of material 
use and costs, for ACL injury under the Brazilian private health care system and eval-
uate epidemiological features on the patients suffering from this injury MethOds: 
A cross-sectional study using Evidencias-Kantar Health database of administrative 
claims regarding surgical procedures for ACL lesions. This database comprizes 4 mil-
lion lives, all covered by 46 different private health insurance companies. All claims 
involving surgical therapy for ACL lesions throughout the year of 2014 were included. 
Only high cost materials were considered in cost calculation (low cost materials, 
surgical team fees, drugs and physical therapy were not included). Results: There 
were 286 cases identified. Patients mean age was 31.64 years, 75.17% were males. In 
84.61% of the cases there were associated meniscal injuries and surgical interven-
tions were indicated for 86.7% of these (91% of the proposed meniscal interventions 
were meniscectomies). Concomitant chondroplasty was necessary in 76.22% of the 
cases, 94% of those by using bipolar radiofrequency. Regarding the use of interfer-
ence screws, 23.77% of those were of the absorbable kind and 76.22% were made 
of titanium. Additional graft fixation with endobutton repair was needed in 27.6% 
of all cases. Considering pricing lists for a standard procedure (including shaver 
systems, guide systems for screws, interference screws), this costs U$1,945 per 
procedure. The use of absorbable screws increased the costs to U$2,370 and the 
additional use of bipolar radiofrequency for chondroplasty adds U$967 to the costs 
per procedure cOnclusiOns: There is wide variation on the surgical materials 
used for ACL repair in Brazil. Since there is no scientific evidence of functional 
benefit by using absorbable screws, or either bipolar radiofrequency systems, a 
standardization of materials for ACL surgical repair would spare significant costs 
to private healthcare payers in Brazil
PMD11
cost-effectiveness of tHe use of 18fDg-Pet/ct in tHe Detection of 
RecuRRent DiffeRentiateD tHyRoiD canceR
Biz AN1, Schluckebier LF2, Bastos CR1, Silva RM3, Braga JU1, Caetano R1
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Objectives: To estimate the cost-effectiveness of the addition of positron emis-
sion tomography with 18F-FDG (18FDG-PET/CT) to conventional Methodsin the 
detection of recurrent differentiated thyroid carcinoma (DTC). MethOds: An 
analytic decision model was developed, based on international guidelines and 
Ministry of Health´s recent clinical protocol. The reference population repre-
sented a hypothetical cohort of adult patients with high risk by initial stratifi-
cation, submitted to total thyroidectomy and ablation with I131. Conventional 
staging was compared to the addition of 18FDG-PET/CT applied to subjects with 
negative Resultson scintigraphy with I131. Clinical parameters and technologies´ 
accuracy were based on literature evidence. The model was designed from the 
perspective of the Brazilian public health care system (SUS), with time horizon 
of 10 years. Effectiveness was measured by additional recurrent cases detected. 
Only direct medical costs were considered. 18FDG-PET/CT costs were estimated 
by micro-costing technique. Costs and benefits were discounted by 5%. Univariate 
deterministic and probabilistic sensitivity analyzes were performed to explore 
